Page last updated: 2024-12-10

myricitrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

myricitrin: isolated from root bark of Myrica cerifera L.; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

myricitrin : A glycosyloxyflavone that consists of myricetin attached to a alpha-L-rhamnopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Myrica cerifera, it exhibits anti-allergic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
MyricagenusA plant genus of the family MYRICACEAE. Members contain myricanol. The common name of bayberry is similar to the name barberry which is used for BERBERIS and MAHONIA.[MeSH]MyricaceaeA plant family of the order Myricales, subclass Hamamelidae, class Magnoliopsida. They are trees and shrubs having aromatic leaves that often have yellow glandular dots on the surface. Single-seeded fruits are often covered with waxy granules, bumps, or layers. The flowers are small, greenish, and inconspicuous.[MeSH]
Myrica ceriferaspecies[no description available]MyricaceaeA plant family of the order Myricales, subclass Hamamelidae, class Magnoliopsida. They are trees and shrubs having aromatic leaves that often have yellow glandular dots on the surface. Single-seeded fruits are often covered with waxy granules, bumps, or layers. The flowers are small, greenish, and inconspicuous.[MeSH]

Cross-References

ID SourceID
PubMed CID5281673
CHEMBL ID522983
CHEBI ID70082
SCHEMBL ID226022
MeSH IDM0052543

Synonyms (70)

Synonym
AC-638
MEGXP0_000257
MLS000574998 ,
smr000232363
ACON1_000103
nsc-19803
myricetol 3-rhamnoside
nsc19803 ,
myricetin 3-o-.alpha.-l-rhamnopyranoside
myricitroside
myricitrine
myricetin 3-rhamnoside
5,7-dihydroxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
myricetrin
5,7-dihydroxy-3-((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-(3,4,5-trihydroxy-phenyl)-1-benzopyran-4-one
myricetin 3-o-rhamnoside ,
myricitrin
17912-87-7
NCGC00163596-01
NCGC00163596-02
5,7-dihydroxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
HMS2218N08
5,7-dihydroxy-4-oxo-2-(3,4,5-trihydroxyphenyl)-4h-chromen-3-yl 6-deoxy-alpha-l-mannopyranoside
myricetin 3-o-alpha-l-rhamnopyranoside
nsc 19803
3-((6-deoxy-alpha-l-mannopyranosyl)oxy)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-benzopyran-4-one
einecs 241-856-7
5z0zo61wpj ,
unii-5z0zo61wpj
flavone,3,3',4',5,5',7-hexahydroxy-,3-rhamnoside
chebi:70082 ,
CHEMBL522983
AKOS015896842
myricitrin [inci]
4h-1-benzopyran-4-one, 3-((6-deoxy-.alpha.-l-mannopyranosyl)oxy)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-
fema no. 4491
myricetin 3-o-rhamnopyranoside
3,3',4',5,5',7-hexahydroxyflavone, 3-rhamnoside
myricetin 3-o-.alpha.-l-rhamnpyronoside
SCHEMBL226022
bdbm153266
myricitrin (7)
CCG-208406
mfcd00016930
3-[(2s,3r,4r,5r,6s)-6-methyl-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)-2-[3,4,5-tris(oxidanyl)phenyl]chromen-4-one
bdbm34753
5,7-dihydroxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2-(3,4,5-trihydroxyphenyl)chromone
cid_5281673
5,7-dihydroxy-3-[[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-2-oxanyl]oxy]-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-4-one
(3-phenylaminocarbonylphenyl)boronicacid
4h-1-benzopyran-4-one, 3-[(6-deoxy-.alpha.-l-mannopyranosyl)oxy]-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-
myricetin-3-rhamnoside
DCYOADKBABEMIQ-OWMUPTOHSA-N
5,7-dihydroxy-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-2-(3,4,5-trihydroxyphenyl)-4h-chromen-4-one
3-[(6-deoxy-|a-l-mannopyranosyl)oxy]-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-benzopyran-4-one
DTXSID40170771
myricitrin, analytical standard
myricitrin, >=99.0% (hplc)
sr-01000712005
SR-01000712005-3
myricitrin, primary pharmaceutical reference standard
myricetin 3- rhamnoside
3-[(6-deoxy-alpha-l-mannopyranosyl)oxy]-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-1-benzopyran-4-one
HY-N0152
myricitrin (myricitrine)
S2327
BS-16289
5,7-dihydroxy-3-((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-2-(3,4,5-trihydroxyphenyl)-4h-chromen-4-one
Q6948223
CS-0007883

Research Excerpts

Overview

Myricitrin (MYR) is a natural flavonoid that inhibits nitric oxide (NO) transmission and has an atypical antipsychotic-like profile in animal models. It is mainly derived from the bark and leaves of the Chinese Bayberry tree (Myrica rubra)

ExcerptReferenceRelevance
"Myricitrin is a natural polyhydroxy flavonoid and is mainly derived from the bark and leaves of the Chinese Bayberry tree (Myrica rubra). "( Unveiling interaction mechanisms between myricitrin and human serum albumin: Insights from multi-spectroscopic, molecular docking and molecular dynamic simulation analyses.
Li, H; Mao, B; Niu, T; Yan, P; Zhang, W; Zhao, D; Zhao, L; Zhao, P; Zhu, X, 2023
)
2.62
"Myricitrin is a flavonol glycoside possessing beneficial effects on obesity, a rising global health issue that affects millions of people worldwide. "( Myricitrin
Deng, C; Huang, J; Yang, K; Yang, L; Yin, P, 2023
)
3.8
"Myricitrin is a newfound natural polyphenol hydroxy flavonoid glycoside compound, whose forceful anti-oxidative properties had been confirmed."( Myricitrin protects against cisplatin-induced kidney injury by eliminating excessive reactive oxygen species.
Hu, C; Hu, L; Lei, Y; Li, R; Wang, Q; Zhao, B, 2020
)
2.72
"Myricitrin (Myr) is a flavonoid compound extracted from myrica rubra with potent anti-inflammatory properties, as demonstrated in various studies."( The protective effect of myricitrin in osteoarthritis: An in vitro and in vivo study.
Lin, J; Lin, Z; Pan, X; Qi, W; Shen, J; Wu, Y; Xue, X; Yan, Z; Zhan, J, 2020
)
1.58
"Myricitrin is a natural occurring flavonoid glycoside that possesses effects on inhibiting nitric oxide (NO) transmission and preventing inflammatory reaction. "( Inhibition effects of a natural inhibitor on RANKL downstream cellular signalling cascades cross-talking.
Gao, W; Hao, D; He, B; Kong, L; Pan, H; Wang, B; Xiao, Y; Zhang, Z, 2018
)
1.92
"Myricitrin is a plant-derived antioxidant, and its solid lipid nanoparticle (SLN) may be more potent."( Solid Lipid Nanoparticles of Myricitrin Have Antioxidant and Antidiabetic Effects on Streptozotocin-Nicotinamide-Induced Diabetic Model and Myotube Cell of Male Mouse.
Ahangarpour, A; Badavi, M; Khorsandi, L; Kouchak, M; Oroojan, AA, 2018
)
1.49
"Myricitrin (MYR) is a natural flavonoid that inhibits nitric oxide (NO) transmission and has an atypical antipsychotic-like profile in animal models. "( Myricitrin induces antidepressant-like effects and facilitates adult neurogenesis in mice.
Andreatini, R; Campos, AC; de Oliveira, RM; Guimarães, FS; Meyer, E; Milani, H; Mori, MA, 2017
)
3.34
"Myricitrin is a nitric oxide (NO) and protein kinase C (PKC) inhibitor that has central nervous system activity, including anxiolytic-like action. "( Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models.
Andreatini, R; Chioca, LR; Correia, D; Pereira, M; Pizzolatti, MG; Santos, AR; Siba, IP; Vital, MA, 2011
)
3.25

Effects

Myricitrin has many pharmacological effects, such as anti-inflammation, liver protection and anti-oxidation. The protective effects of myricitin against liver ischemia reperfusion (I/R) injury are still unexplored.

ExcerptReferenceRelevance
"Myricitrin (Myr) has an antioxidant effect along with low bioavailability."( Hyperglycemia-induced oxidative stress in isolated proximal tubules of mouse: the in vitro effects of myricitrin and its solid lipid nanoparticle.
Ahangarpour, A; Badavi, M; Khorsandi, L; Kouchak, M; Oroojan, AA, 2021
)
1.56
"Myricitrin has many pharmacological effects, such as anti-inflammation, liver protection and anti-oxidation. "( Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes.
Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019
)
2.18
"Myricitrin has been reported to exert protective effects on liver diseases, but the protective effects of myricitrin against liver ischemia reperfusion (I/R) injury and the underlying mechanisms remain unexplored. "( Myricitrin pretreatment ameliorates mouse liver ischemia reperfusion injury.
Cheng, Y; Liu, Y; Shen, X; Shen, Y, 2020
)
3.44
"Myricitrin has multiple effects, including antagonism of platelet activating factor, regulation of blood sugar levels, oxidation resistance, protection of the liver and the relieving of ethylism. "( Myricitrin decreases traumatic injury of the spinal cord and exhibits antioxidant and anti‑inflammatory activities in a rat model via inhibition of COX‑2, TGF‑β1, p53 and elevation of Bcl‑2/Bax signaling pathway.
Lei, Y, 2017
)
3.34
"Myricitrin (Myr) has an antioxidant effect along with low bioavailability."( Hyperglycemia-induced oxidative stress in isolated proximal tubules of mouse: the in vitro effects of myricitrin and its solid lipid nanoparticle.
Ahangarpour, A; Badavi, M; Khorsandi, L; Kouchak, M; Oroojan, AA, 2021
)
1.56

Actions

ExcerptReferenceRelevance
"Myricitrin can enhance the activities of anti-oxidative enzymes and decrease the production of free radicals."( [Protect effects and the underlying mechanisms of myricitrin against vascular endothelial cells apoptosis induced by oxidative stress].
Luo, Y; Meng, XB; Pan, RL; Qin, M; Sun, GB; Sun, XB; Wang, M; Zou, YH, 2013
)
1.36

Treatment

Myricitrin treatment significantly reduced cell proliferation by more than 50 %. The treatment of Myricitin showed improved memory in MWM compared to rats treated with vehicle. The effects of My Ricitrin were similar to sodium butyrate-treated rats.

ExcerptReferenceRelevance
"Myricitrin treatment reduced the mitochondrial membrane potential (22.95%), increased DNA fragmentation (90.4%), inhibited the cell survival proteins (RAS, B-RAF, & BCL-2) and also induced pro-apoptotic proteins (p38, pro-caspase-3, pro-caspase-9 and caspase-3) in the HL-60 cells."( Apoptotic mechanisms of myricitrin isolated from Madhuca longifolia leaves in HL-60 leukemia cells.
Jayaraman, A; Kar, A; Mahapatra, SK; Sarkar, MK; Shanmugam, K; Vadivel, V, 2021
)
1.65
"Myricitrin treatment significantly reduced cell proliferation by more than 50 %."( Myricitrin inhibits vascular endothelial growth factor-induced angiogenesis of human umbilical vein endothelial cells and mice.
Cheng, H; Gou, W; Hu, Z; Zhao, G, 2020
)
2.72
"Myricitrin treatment also prevents and attenuates H2O2-induced endothelial injury."( Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice.
Li, ZY; Luo, Y; Meng, XB; Pan, RL; Qin, M; Sun, GB; Sun, XB; Wang, HW; Wang, M; Ye, JX, 2013
)
1.43
"Myricitrin pretreatment could attenuate H2O2-induced increase of p-ERK."( [Protect effects and the underlying mechanisms of myricitrin against vascular endothelial cells apoptosis induced by oxidative stress].
Luo, Y; Meng, XB; Pan, RL; Qin, M; Sun, GB; Sun, XB; Wang, M; Zou, YH, 2013
)
1.36
"Myricitrin pre-treatment prevented cytokine-induced biting behaviour."( Involvement of p38MAPK on the antinociceptive action of myricitrin in mice.
Leal, RB; Meotti, FC; Missau, FC; Pizzolatti, MG; Posser, T; Santos, AR, 2007
)
1.31
"The treatment of Myricitrin showed improved memory in MWM compared to rats treated with vehicle, and the effects of Myricitrin were similar to sodium butyrate-treated rats."( Myricitrin ameliorates cognitive deficits in MCAO cerebral stroke rats via histone acetylation-induced alterations of brain-derived neurotrophic factor.
Gao, Y; Guo, Y; Li, X; Ya, B; Yin, H, 2021
)
2.39
"Treatment with myricitrin significantly attenuated ox-LDL-induced endothelial cell apoptosis by inhibiting LOX-1 expression and by increasing the activation of the STAT3 and PI3K/Akt/eNOS signaling pathways."( Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K/Akt activation and STAT3 signaling pathways.
Luo, Y; Meng, XB; Pan, RL; Qin, M; Song, SY; Sun, GB; Sun, XB; Wang, HW; Wang, M; Wu, P; Yao, F; Ye, JX, 2015
)
2.2

Toxicity

ExcerptReferenceRelevance
" Our studies did not reveal evidence of genotoxic potential of myricitrin in vivo, supporting its safe use in food and beverages."( Genotoxicity evaluation of the flavonoid, myricitrin, and its aglycone, myricetin.
Davis, J; Hayashi, SM; Hobbs, CA; Koyanagi, M; Maronpot, R; Recio, L; Swartz, C, 2015
)
0.92
" It is affirmed as generally recognised as safe (GRAS) by the US Flavour and Extract Manufacturer Association (FEMA) and is considered safe by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) at current estimated dietary exposures."( Safety assessment and single-dose toxicokinetics of the flavouring agent myricitrin in Sprague-Dawley rats.
Boyle, M; Davis, J; Hayashi, SM; Koyanagi, M; Marbury, D; Maronpot, RR; Recio, L, 2015
)
0.65

Pharmacokinetics

ExcerptReferenceRelevance
" The in vitro release of MPs compared with free myricitrin was measured in different dissolution media while the pharmacokinetic study was also conducted in rats."( Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes.
Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019
)
0.99

Bioavailability

ExcerptReferenceRelevance
" Development of COMT inhibitors can efficiently increase the bioavailability of L-dopa."( Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromyricetin, and myricitrin.
Jia, YH; Zhu, X, 2014
)
0.63
" Therefore, we conclude that the low bioavailability of these flavonoids may be due to their poor stability in the GI tract."( Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation.
Fang, JG; Shi, CY; Wang, CG; Wang, MD; Wang, WQ; Xiang, D; Xiong, W, 2017
)
0.69
"This study was designed to investigate the bioavailability and targeting of myricetrin-loaded ternary micelles modified with and without TPGS."( The characterisation, pharmacokinetic and tissue distribution studies of TPGS modified myricetrin mixed micelles in rats.
Adu-Frimpong, M; Ji, H; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xie, Y; Xu, X; Yu, J, 2019
)
0.51
" Notably, compared with the free myricitrin, the cumulative release in vitro and in vivo oral bioavailability of MPs were markedly increased."( Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes.
Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019
)
1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
anti-allergic agentA drug used to treat allergic reactions.
EC 1.14.13.39 (nitric oxide synthase) inhibitorAn EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of nitric oxide synthase (EC 1.14.13.39).
EC 2.7.11.13 (protein kinase C) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pentahydroxyflavoneA hydroxyflavone substituted by five hydroxy groups.
glycosyloxyflavoneA member of the class of flavones having one or more glycosyl residues attached at unspecified positions.
alpha-L-rhamnoside
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency12.06270.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.89130.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency10.40570.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency31.62280.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency2.23870.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency28.18380.125919.1169125.8920AID2549
phosphopantetheinyl transferaseBacillus subtilisPotency43.92850.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency15.84890.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency10.66550.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
hypothetical protein, conservedTrypanosoma bruceiPotency50.11870.223911.245135.4813AID624173
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency44.66840.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.16230.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency8.91250.006026.168889.1251AID540317
DNA polymerase betaHomo sapiens (human)Potency10.00000.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency2.62590.133725.412989.1251AID588795; AID720498
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency37.68580.168316.404067.0158AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency39.81070.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency39.81070.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency62.65580.050127.073689.1251AID588590; AID720496
DNA polymerase kappa isoform 1Homo sapiens (human)Potency13.40120.031622.3146100.0000AID588579
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency12.58930.00419.962528.1838AID2675
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency89.12516.309660.2008112.2020AID720709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
integrase, partialHuman immunodeficiency virus 1IC50 (µMol)4.94400.07953.52039.9390AID1053171; AID1053172
lens epithelium-derived growth factor p75Homo sapiens (human)IC50 (µMol)4.94400.07953.52039.9390AID1053171; AID1053172
MPI proteinHomo sapiens (human)IC50 (µMol)30.96500.190013.825650.1000AID1220
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)220.00000.03403.987110.0000AID1505136; AID1505139
RNA-editing ligase 1, mitochondrialTrypanosoma brucei bruceiIC50 (µMol)51.38100.41081.47173.5100AID1117295
Aurora kinase BHomo sapiens (human)IC50 (µMol)3.89000.00030.96349.8000AID1801097
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 beta isoform 1Homo sapiens (human)EC50 (µMol)300.00000.212522.156283.9400AID434954
POsterior SegregationCaenorhabditis elegansEC50 (µMol)15.80502.201047.1808186.6810AID1964
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)14.04700.082031.0243168.9080AID1960
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)14.04700.082033.5679168.9080AID1960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prolyl 4-hydroxylase, beta polypeptideHomo sapiens (human)AC509.80000.015512.834845.2600AID602350; AID624274
Receptor-type tyrosine-protein phosphatase betaHomo sapiens (human)Kis125.70003.73005.66507.6000AID775020
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (71)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
phosphate-containing compound metabolic processReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
glial cell migrationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
dephosphorylationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
angiogenesisReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
cadherin bindingReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
specific granule membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
tertiary granule membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
receptor complexReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1505136Inhibition of mushroom tyrosinase using L-tyrosine as substrate pretreated for 5 mins followed by substrate addition measured over 30 mins by spectrophotometric method2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation of Flavonoids and Flavonoid Glycosides from Myrsine africana and Their Inhibitory Activities against Mushroom Tyrosinase.
AID1516848Antifungal activity against Candida tropicalis 166 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1516851Antifungal activity against Candida albicans 498 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1316658Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1376889Antimicrobial activity against Pseudomonas aeruginosa DSM 50071 assessed as growth inhibition at 40 ug per disc after 24 to 48 hrs (Rvb = 0 millimeter)
AID404012In vivo antitumor activity against mouse LLC cells
AID1365686Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM incubated for 24 hrs under dark condition by thioflavin-T based fluorometric assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Flavonoids and their derivatives with β-amyloid aggregation inhibitory activity from the leaves and twigs of Pithecellobium clypearia Benth.
AID1316659Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1316657Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1376888Antimicrobial activity against Bacillus cereus DSM 4313 assessed as growth inhibition at 40 ug per disc after 24 to 48 hrs (Rvb = 0 millimeter)
AID1428458Inhibition of mushroom tyrosinase using L-DOPA as substrate preincubated for 5 mins followed by substrate addition measured for 10 mins by spectrophotometric method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase.
AID1516852Antifungal activity against Candida albicans 53 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1428456Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase.
AID1607877Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS induced TNF-alpha at 100 uM preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by ELISA relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Human disorders associated with inflammation and the evolving role of natural products to overcome.
AID1516856Antifungal activity against Candida glabrata 587 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1505137Antioxidant activity assessed as DPPH radical scavenging activity measured after 30 mins incubation under dark condition2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation of Flavonoids and Flavonoid Glycosides from Myrsine africana and Their Inhibitory Activities against Mushroom Tyrosinase.
AID1376874Cytotoxicity against human A549 cells at 10 to 100 uM by MTT assay
AID404070In vivo antitumor activity against mouse CA-755 cells
AID1516853Antifungal activity against Candida albicans ATCC 10231 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID775020Competitive inhibition of human GST-tagged LMW-PTP-B expressed in Escherichia coli JM 109 cells using p-nitrophenyl phosphate as substrate after 15 mins by microplate reader analysis2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.
AID1376887Antimicrobial activity against Escherichia coli DSM 8579 assessed as growth inhibition at 40 ug per disc after 24 to 48 hrs (Rvb = 0 millimeter)
AID641626Inhibition of Mycobacterium tuberculosis RmlD assessed as inhibition of dTDP-beta-6-deoxy-L-lyxo-4-hexulose to dTDP-beta-L-rhamnose conversion at 10 ug/ml2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening.
AID404067In vivo antitumor activity against mouse S180 cells
AID1428457Inhibition of Acyrthosiphon pisum phenoloxidase using L-DOPA as substrate preincubated for 5 mins followed by substrate addition measured after 120 to 240 mins by spectrophotometric method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase.
AID1516858Antifungal activity against Candida glabrata 493 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1505139Inhibition of mushroom tyrosinase2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation of Flavonoids and Flavonoid Glycosides from Myrsine africana and Their Inhibitory Activities against Mushroom Tyrosinase.
AID1376890Antimicrobial activity against Staphylococcus aureus DSM 25923 assessed as growth inhibition at 40 ug per disc after 24 to 48 hrs (Rvb = 0 millimeter)
AID1376875Cytotoxicity against human DeFew cells at 10 to 100 uM by MTT assay
AID1316661Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1516849Antifungal activity against Candida krusei 168 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1376873Antioxidant activity in human plasma assessed as inhibition of H2O2/Fe2+-induced lipid peroxidation at 10 uM after 30 mins by TBARS assay relative to control
AID1516847Antifungal activity against Candida parapsilosis 96 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1376886Antimicrobial activity against Bacillus cereus DSM 4384 assessed as growth inhibition at 40 ug per disc after 24 to 48 hrs (Rvb = 0 millimeter)
AID1516854Antifungal activity against Candida glabrata 507 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1516855Antifungal activity against Candida glabrata 531 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1281980Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by microplate reader analysis2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
α-Glucosidase inhibition and antihyperglycemic activity of flavonoids from Ampelopsis grossedentata and the flavonoid derivatives.
AID404069In vivo antitumor activity against mouse L1210 cells
AID1316660Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID404008Cytotoxicity against human KB cells
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID1376872Antioxidant activity in human plasma assessed as inhibition of H2O2-induced lipid peroxidation at 10 uM after 30 mins by TBARS assay relative to control
AID1516859Antifungal activity against Candida glabrata 482 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1516850Antifungal activity against Candida albicans 501 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1516857Antifungal activity against Candida glabrata 510 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1801097Aurora B Kinase Assay from Article 10.1111/cbdd.12445: \\Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.\\2015Chemical biology & drug design, May, Volume: 85, Issue:5
Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.85)18.7374
1990's1 (0.85)18.2507
2000's19 (16.24)29.6817
2010's70 (59.83)24.3611
2020's26 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.51 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index6.19 (4.65)
Search Engine Demand Index45.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.36%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other115 (96.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]